The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study
Abstract
Background— The antiplatelet effects of the Platelet Inhibition and Patient Outcomes (PLATO) trial dose of ticagrelor in patients nonresponsive to clopidogrel and after they switch agents are unknown. Methods and Results— Patients with stable coronary artery disease on aspirin therapy received a 300-mg clopidogrel load; nonresponders were identified by light transmittance aggregometry. In a 2-way crossover design, nonresponders (n=41) and responders (n=57) randomly received clopidogrel (600 mg/75 mg once daily) or ticagrelor (180 mg/90 mg twice daily) for 14 days during period 1. In period 2, all nonresponders switched treatment; half of the responders continued the same treatment, whereas the others switched treatment. Inhibition of platelet aggregation was higher in nonresponders treated with ticagrelor compared with clopidogrel ( P <0.05). Treatment with ticagrelor among nonresponders resulted in a >10%, >30%, and >50% decrease in platelet aggregation from baseline in 100%, 75%, and 13% of patients, respectively. Platelet aggregation fell from 59±9% to 35±11% in patients switched from clopidogrel to ticagrelor and increased from 36±14% to 56±9% in patients switched from ticagrelor to clopidogrel ( P <0.0001 for both). Platelet reactivity was below the cut points previously associated with ischemic risk measured by light transmittance aggregometry, VerifyNow P2Y 12 assay, and vasodilator-stimulated phosphoprotein phosphorylation in 98% to 100% of patients after ticagrelor therapy versus 44% to 76% of patients after clopidogrel therapy. Conclusions— Ticagrelor therapy overcomes nonresponsiveness to clopidogrel, and its antiplatelet effect is the same in responders and nonresponders. Nearly all clopidogrel nonresponders and responders treated with ticagrelor will have platelet reactivity below the cut points associated with ischemic risk. Clinical Trial Registration— http://www.clinicaltrials.gov. Unique Identifier: NCT00642811.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting
Leon, M. B., Baim, D. S., Popma, J. J., Gordon, P. C., Cutlip, D. E., Ho, K. K. L., Giambartolomei, A., Diver, D. J., Lasorda, D. M., Williams, D. O., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392303 · Cited by 1,815
Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O’Connor, C. M. (2003) · Circulation · doi:10.1161/01.cir.0000072771.11429.83 · Cited by 1,544
Self-citationMatetzky, S., Shenkman, B., Guetta, V., Shechter, M., Beinart, R., Goldenberg, I., Novikov, I., Pres, H., Savion, N., Varon, D., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130846.46168.03 · Cited by 1,354
Gurbel, P. A., Bliden, K. P., Butler, K., Tantry, U. S., Gesheff, T., Wei, C., Teng, R., Antonino, M. J., Patil, S. B., Karunakaran, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.912550 · Cited by 1,159
Self-citationWiviott, S. D., Trenk, D., Frelinger, A. L., O’Donoghue, M., Neumann, F.-J., Michelson, A. D., Angiolillo, D. J., Hod, H., Montalescot, G., Miller, D. L., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.740324 · Cited by 881
Patrono, C., Baigent, C., Hirsh, J., & Roth, G. (2008) · Chest · doi:10.1378/chest.08-0672 · Cited by 748
Husted, S., Emanuelsson, H., Heptinstall, S., Sandset, P. M., Wickens, M., & Peters, G. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi754 · Cited by 743
Self-citationPrice, M. J., Endemann, S., Gollapudi, R. R., Valencia, R., Stinis, C. T., Levisay, J. P., Ernst, A., Sawhney, N. S., Schatz, R. A., & Teirstein, P. S. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn046 · Cited by 651
Cited by
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationCollet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Self-citationJoseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
James, S., Angiolillo, D. J., Cornel, J. H., Erlinge, D., Husted, S., Kontny, F., Maya, J., Nicolau, J. C., Spinar, J., Storey, R. F., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq325 · Cited by 446
Self-citationACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
Holmes, D. R., Dehmer, G. J., Kaul, S., Leifer, D., O’Gara, P. T., & Stein, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.013 · Cited by 354
Metadata
- Authors
- Gurbel, P. A., Bliden, K. P., Butler, K., Antonino, M. J., Wei, C., Teng, R., Rasmussen, L., Storey, R. F., Nielsen, T., Eikelboom, J. W., Sabe-Affaki, G., Husted, S., Kereiakes, D. J., Henderson, D., Patel, D. V., & Tantry, U. S.
- Venue
- Circulation
- Published
- 2010-03-16
- Volume
- 121
- Issue
- 10
- Pages
- 1188-1199
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2170312517
- Cited by
- 447
- References
- 23
- FWCI
- 40.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study. https://app.cochat.ai/papers/10.1161/circulationaha.109.919456
- The paper
- Gurbel, P. A., Bliden, K. P., Butler, K., Antonino, M. J., Wei, C., Teng, R., Rasmussen, L., Storey, R. F., Nielsen, T., Eikelboom, J. W., Sabe-Affaki, G., Husted, S., Kereiakes, D. J., Henderson, D., Patel, D. V., & Tantry, U. S. (2010). Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study. Circulation. https://doi.org/10.1161/circulationaha.109.919456
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
